

1 **Gut microbiota-CRAMP axis shapes intestinal barrier function and**
2 **immune responses in dietary gluten-induced enteropathy**

3 **Appendix**

4 **Table of contents**

Contents	Pages
Appendix Table S1: The characteristics of human subjects	2
Appendix Table S2: Primers used for RT-qPCR	3
Appendix Supplementary Methods	4-9

5

6 **Appendix Tables**

7 **Appendix Table S1: The characteristics of human subjects (no. or mean \pm SD).**

8 **Related to Materials and Methods.**

	Double	Anti-tTG	Anti-DGP	Double
Variables	Negative	IgA⁺	IgG⁺	Positive
	(n=50)	(n=46)	(n=50)	(n=13)
Age, yr	18.72 \pm 1.11	18.61 \pm 0.94	19.06 \pm 1.34	18.7 \pm 0.57
Men, n (%)	45 (90.0)	29 (63.0)	25 (50.0)	3 (23.1)

9 Anti-Ttg IgA: anti-tissue transglutaminase immunoglobulin A antibodies

10 Anti-DGP IgG: anti-deamidated gliadin peptides immunoglobulin G antibodies

11

12 **Appendix Table S2: Primers used for RT-qPCR. Related to Materials and**
 13 **Methods.**

Gene	Forward	Reverse
<i>Il15</i>	5'-ACATCCATCTCGTGCTACTTGTA-3'	5'-GCCTCTGTTTTAGGGAGACCT-3'
<i>IL15</i>	5'-TTGGGAACCATAGATTTGTGCAG-3'	5'-GGGTGAACATCACTTTCCGTAT-3'
<i>Ifng</i>	5'-ATGAACGCTACACACTGCATC-3'	5'-CCATCCTTTTGCCAGTTTCT-3'
<i>Il6</i>	5'-TAGTCCTTCCTACCCCAATTTCC-3'	5'-TTGGTCCTTAGCCACTCCTTC-3'
<i>Il8</i>	5'-GACTCTTGCGTCAACTTCAAGG-3'	5'-CAGGCTGTCTTTGTCAACGA-3'
<i>Il27</i>	5'-CTGTTGCTGCTACCCTTGCTT-3'	5'-CACTCCTGGCAATCGAGATTC-3'
<i>Ccl2</i>	5'-TTAAAAACCTGGATCGGAACCA-3'	5'-GCATTAGCTTCAGATTTACGGGT- 3'
<i>COX2</i>	5'-GGGTGTGAAGGGAAATAAGG-3'	5'-TGTGATTTAAGTCCACTCCATG-3'
<i>Ifna</i>	5'-GCAATCCTCCTAGACTCACTTCTGCA- 3'	5'-TATAGTTCCTCACAGCCAGCAG-3'
<i>Ccl5</i>	5'-GCTGCTTTGCCTACCTCTCC-3'	5'-TCGAGTGACAAACACGACTGC-3'
<i>Il23</i>	5'-ATGCTGGATTGCAGAGCAGTA-3'	5'-ACGGGGCACATTATTTTTAGTCT-3'
<i>Il2</i>	5'-TGGTTTGCCATCGTTTTGCTG-3'	5'-ACAGGTGAGGTTCACTGTTTCT-3'
<i>Paeruginosa</i>	5'-CTGGGTCGAAAGGTGGTTGTTATC-3'	5'-GCGGCTGGTGCGGCTGAGTC-3'
<i>A. mucini phila</i>	5'-CAGCACGTGAAGGTGGGGAC-3'	5'-CCTTGCGGTTGGCTTCAGAT-3'
<i>lasB</i>	5'- GTCGACTCTAGAGGATCCCCTGGCCCCT CGCTGAGCGC-3'	5'- AGAATTCGAGCTCGGTACCCCTGGC GGAAGACGGCTTGAGC-3'
<i>16S</i>	5'-GCAGGCCTAACACATGCAAGTC-3'	5'-CTGCTGCCTCCCGTAGGAGT-3'
<i>Actb</i>	5'-CCCAGGCATTGCTGACAGG-3'	5'-TGGAAGGTGGACAGTGAGGC-3'

14

15 **Appendix Supplementary Methods**

16 **The isolation of IECs, IELs and LP**

17 IECs, IELs and LP cells were extracted from the small intestine. Briefly, the small
18 intestine was collected and the Peyer patches were removed. Intestines were opened
19 longitudinally, cut into pieces of 5 mm, and washed extensively in ice-cold Hank's
20 Balanced Salt Solution wash solution (HBSS; Mg²⁺- and Ca²⁺-free; Beyotime,
21 Shanghai, China). IECs and IELs cells suspension were then collected by twice
22 incubations of intestinal pieces for 20 minutes at 37°C in HBSS containing 5 mM
23 Ethylenediaminetetraacetic acid, 1 mM Dithiothreitol and 10% fetal calf serum. IECs
24 was separated from IELs in supernatant through Percoll (Sigma, Shanghai, China).
25 Intestinal pieces were then washed in RPMI 1640 medium containing 10% fetal calf
26 serum, then cut into small pieces and incubated for 30 minutes at 37°C with a solution
27 of RPMI 1640 medium containing 1 mg·mL⁻¹ DNase (Sigma, Shanghai, China) and 1
28 mg·mL⁻¹ collagenase type IV (Sangon Biotech, Shanghai, China) to obtain a
29 homogeneous LP cells suspension.

30 **Microbiota composition analyses**

31 Total DNA was extracted from duodenal content using the Fast DNA Spite Kit for Feces
32 (MP Biomedicals, Shanghai, China) according to the manufacturer's instructions. The
33 PCR amplification products were separated by 1.0% agarose Gel electrophoresis, and
34 used the Gel/PCR Extraction Kit (BIOMIGA, CA, USA) to recover the target fragments.
35 DNA was extracted from samples and amplified for the hypervariable 16S rRNA gene
36 v3 to v4. Products were then sequenced using the Illumina MiSeq platform (Jiangsu,

37 China).

38 **Antibodies for western blot**

39 Antibody for CRAMP pAb (1:1,000, PA-CRPL-100) was purchased from Innovagen
40 AB (Lund, Sweden). claudin-1 pAb (1:5,000, ab180158), occludin pAb (1:1,000,
41 ab216327), zonulin pAb (1:10,000, ab131236) TRAF6 pAb (1:5,000, ab40675) and p65
42 pAb (1:50,000, ab32536) were purchases from Abcam (Cambridge, UK). Antibodies
43 for p-AKT mAb (4060S), Akt mAb (4685S), MyD88 mAb (4283S) and p-p65 mAb
44 (3033S) (all in 1:1,000) were purchased from Cell Signaling Technology (MA, USA).
45 Antibodies for ZO-1 mAb (1:500, 40-2200) and ZO-2 pAb (1:250, 71-1400) were
46 purchased from ThermoFisher Scientific (MA, USA). Antibody for β -actin mAb
47 (1:200,000, AC026) was purchased from Abclonal Technology (Hubei, China).

48 **Preparation of pepsin/trypsin digested (PT)-gliadin**

49 PT-gliadin was prepared by enzymatic digestion as described previously (Frazer *et al*,
50 1959). Briefly, 5 g of gliadin (Sigma, Shanghai, China) was dissolved in 50 mL of 0.2
51 N HCl for 2 h at 37°C with 0.1 g of pepsin (Sigma, Shanghai, China). The resultant
52 peptic digest was further digested by the addition of 0.1 g of trypsin (Sigma, Shanghai,
53 China) after the pH was adjusted to 7.4 using 2 M NaOH. The solution was stirred
54 vigorously at 37°C for 4 h, boiled (100°C) for 30 min, freeze-dried, lyophilized in 10-
55 mg aliquots, and stored at -20°C until use.

56 **Gut permeability assay**

57 For assessment for gut permeability, 4 hours fasted mice received 500 mg·kg⁻¹ FITC-
58 Dextran 4000 (Sigma, Shanghai, China) intragastrically and blood collected 4 hour later.

59 Serum concentration of FITC-dextran was determined by fluorometry (excitation 485
60 nm; emission 520 nm on a FLUOstar Optima microplate reader; BMG Labtech) relative
61 to standard curve generated from serial dilution of FITC-dextran in control (non-treated)
62 serum.

63 **Flow cytometry**

64 Single cell suspensions were stained for 30min at 4 °C after FcγRII/III blocking
65 (Miltenyi Biotec, Bergisch Gladbach, Germany). Cell suspensions were then incubated
66 for 15 min at room temperature in PBS with following antibodies: Alexa Fluor® 700
67 anti-mouse CD45 (103128), Brilliant Violet® 711 anti-mouse CD11c (117349),
68 Brilliant Violet® 605 anti-mouse CD11b (101257), APC anti-mouse CD103 (121413),
69 Brilliant Violet® 421 anti-mouse CX3CR1 (149023), Brilliant Violet® 421 anti-mouse
70 CD3e (100341), PE anti-mouse CD314 (NKG2D) (130207), APC anti-T-bet (644813),
71 Alexa Fluor® 488 anti-mouse FOXP3 (126405) (BioLegend, CA, USA), PE anti-
72 mouse ROR GAMMA (T) (B2D) (12-6981-80) and PE-Cy™7 anti-mouse CD4
73 (552775; BD biosciences, MD, USA). Gating methods of fluorescence-activated cell
74 sorting were programmed as CD3⁺CD4⁺NKG2D⁺ (for IELs), CD45⁺CD11b⁺CX3CR1⁺
75 (for macrophages) and CD45⁺CD11c⁺CD11b^{+/-}CD103^{+/-} (for dendritic cells),
76 CD3⁺CD4⁺Foxp3⁺ (for Tregs), CD3⁺CD4⁺T-bet⁺ (for Th1) and CD3⁺CD4⁺ROR-γt⁺ (for
77 Th17). The presence of cells displaying aldehyde dehydrogenase activity (ALDH cells)
78 was determined using an ALDEFLUOR staining kit (StemCell Technologies,
79 Vancouver, Canada). Stained cells were analyzed on an Attune NxT flow cytometer
80 (Thermo Fisher Scientific, MA, USA) and data were analyzed using Flow Jo (10.6.2)

81 software (BD Bioscience).

82 **Enzyme-linked immunosorbent assay (ELISA) assays**

83 The levels of CRAMP and LL-37 were analyzed using the mouse CRAMP /human LL-
84 37 ELISA kit (My biosource, Inc., CA, USA).

85 **Histology and immunostaining**

86 Fresh small intestine samples were fixed in 4% paraformaldehyde overnight, washed
87 with running water for 2 h, rehydrated with gradient ethanol, and then embedded in
88 paraffin. The Skiving Machine Slicer (RM2245; Leica, Hessen, Germany) diced 5 µm
89 sections were stained with hematoxylin and eosin (H&E) following the standard
90 procedure. For immunofluorescent staining, the following primary antibodies were
91 applied: anti-CRAMP pAb (1:50, 12009-1-AP; Proteintech, Hubei, China), anti-E-
92 cadherin pAb (1:100, 610181; BD Biosciences, MD, USA), anti-F4/80 mAb and anti-
93 Ly6G mAb (1:100, ab6640, ab25377; Abcam, Cambridge, UK). Anti-rabbit
94 AlexaFluor® 555 (CRAMP), anti-mouse AlexaFluor® 488 (E-cadherin) and anti-rat
95 AlexaFluor® 488 (F4/80 and Ly6G) polyclonal secondary antibodies (all in 1:500,
96 Invitrogen, Shanghai, China) were applied. The DAPI (4',6-diamidino-2-phenylindole)
97 staining was conducted according to the protocol provided by the manufacturer
98 (Beyotime, Shanghai, China). A digital slice scanner (3DHISTCH Ltd, Budapest,
99 Hungary) was used for H&E morphology evaluation. An ultra-high-resolution confocal
100 microscope (LSM880, Carl Zeiss, Baden-Württemberg, Germany) was used for
101 acquisition of immunofluorescence staining. ZEN software (Carl Zeiss) was applied for
102 image processing.

103 **Immunoblotting**

104 Small intestine samples were homogenized in ice-cold lysis buffer RIPA (containing
105 protease inhibitors and phosphatase inhibitors). Protein concentrations were determined
106 by using a BCA Protein Assay Kit (Beyotime, Shanghai, China). Equal amounts of
107 protein were electrophoretically separated in SDS–polyacrylamide gels and then
108 transferred onto PVDF membranes (Millipore, MA, USA). The membranes were
109 blocked with 5% w/v nonfat dry milk in TBS-T for 1 h at room temperature, further
110 incubated with appropriately diluted primary antibodies overnight at 4 °C and probed
111 with secondary peroxidase-labeled antibody for 2 h at room temperature. The proteins
112 were visualized by Plus-enhanced chemiluminescence using FluorChem FC3
113 (ProteinSimple, CA, USA). The densitometric analyses of protein expression by
114 Western blot were performed by AlphaView Software (ProteinSimple).

115 **SCFA measurement by Gas Chromatography–Mass Spectrometry**

116 The short-chain fatty acids (SCFAs) - acetate, propionate and butyrate, present in the
117 fecal were analyzed by Gas Chromatography–Mass Spectrometry (GC/MS). Feces
118 samples (50 mg) were collected directly into sterile tubes from live mice and were first
119 homogenized in 500 µL of saturated NaCl solution. Thereafter, fecal samples were
120 acidified with 40 µL 10% sulfuric acid. 0.8 mL diethyl ether was added to the sample
121 to extract SCFAs. Samples were then centrifuged at 14,000 rpm for 15 min at 4 °C and
122 the supernatants were used for the analyses of the SCFAs. Supernatants were injected
123 into Rtx-WAX capillary column (30 m×0.25 mm×0.25 µm; Shimadzu, Kyoto, Japan)
124 installed on the GC and coupled to the MS detector of GCMS-QP2010 (Shimadzu).

125 The initial oven temperature was 100 °C and increased to 140 °C at a rate of 7.5 °C·min⁻¹.
126 ¹. The temperature was further increased to 200 °C at a rate of 60 °C·min⁻¹ and remained
127 for 3 min. Helium was utilized as the carrier gas at a flow rate of 0.89 mL·min⁻¹, and
128 the column head pressure was 62.7 kPa. The injector was set at 240 °C. The injection
129 mode was split and the ratio was 10:1. For mass spectrometer, ion source temperature
130 was 220 °C, interface temperature was 250 °C, and the scan range was from m/z 2 to
131 100. Real time analysis software GCMS Postrun (GCMS solution Version 2.72,
132 Shimadzu) was employed to compare the relative concentrations of SCFAs.